Critical Contrast: Biorestorative Therapies (NASDAQ:BRTX) & Sensei Biotherapeutics (NASDAQ:SNSE)

Biorestorative Therapies (NASDAQ:BRTX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Biorestorative Therapies and Sensei Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360,000.00	28.99	-$14.24 million	($1.07)	-0.38
Sensei Biotherapeutics	N/A	N/A	-$21.08 million	($142.72)	-0.10

Biorestorative Therapies has higher revenue and earnings than Sensei Biotherapeutics. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Biorestorative Therapies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500.

Insider & Institutional Ownership

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Biorestorative Therapies and Sensei Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Biorestorative Therapies and Sensei Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1	0	0	0	1.00
Sensei Biotherapeutics	1	2	4	0	2.43

Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Biorestorative Therapies.

Summary

Biorestorative Therapies beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

About Biorestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.